PMID- 21733225
OWN - NLM
STAT- MEDLINE
DCOM- 20121019
LR  - 20211020
IS  - 1469-5111 (Electronic)
IS  - 1461-1457 (Print)
IS  - 1461-1457 (Linking)
VI  - 15
IP  - 6
DP  - 2012 Jul
TI  - Distinct periods of developmental sensitivity to the effects of 
      3,4-(+/-)-methylenedioxymethamphetamine (MDMA) on behaviour and monoamines in rats.
PG  - 811-24
LID - 10.1017/S1461145711000952 [doi]
AB  - Previous findings showed allocentric and egocentric learning deficits in rats 
      after MDMA treatment from postnatal days (PD) 11-20 but not after treatment from 
      PD 1-10. Shorter treatment periods (PD 1-5, 6-10, 11-15, or 16-20) resulted in 
      allocentric learning deficits averaged across intervals but not for any interval 
      individually and no egocentric learning deficits individually or collectively. 
      Whether this difference was attributable to treatment length or age at the start 
      of treatment was unclear. In the present experiment rat litters were treated on 
      PD 1-10, 6-15, or 11-20 with 0, 10, or 15 mg/kg MDMA q.i.d. at 2-h intervals. Two 
      male/female pairs/litter received each treatment. One pair/litter received 
      acoustic startle with prepulse inhibition, straight channel swimming, Cincinnati 
      water maze (CWM), and conditioned fear in a latent inhibition paradigm. The other 
      pair/litter received locomotor activity, straight channel swimming, Morris water 
      maze (MWM), and locomotor activity retest with MK-801 challenge. MDMA impaired 
      CWM learning following PD 6-15 or 11-20 exposure. In MWM acquisition, all 
      MDMA-treated groups showed impairment. During reversal and shift, the PD 6-15 and 
      PD 11-20 MDMA-treated groups were significantly impaired. Reductions in locomotor 
      activity were most evident after PD 6-15 treatment while increases in acoustic 
      startle were most evident after PD 1-10 treatment. After MK-801 challenge, 
      MDMA-treated offspring showed less locomotion compared to controls. 
      Region-specific changes in brain monoamines were also observed but were not 
      significantly correlated with behavioural changes. The results show that PD 11-20 
      exposure to MDMA caused the largest long-term cognitive deficits followed by PD 
      6-15 exposure with PD 1-10 exposure least affected. Other effects, such as those 
      upon MK-801-stimulated locomotion showed greatest effects after PD 1-10 MDMA 
      exposure. Hence, each effect has a different window of developmental 
      susceptibility.
FAU - Skelton, Matthew R
AU  - Skelton MR
AD  - Division of Neurology, Cincinnati Children's Research Foundation and the 
      Department of Pediatrics, University of Cincinnati College of Medicine, 
      Cincinnati, OH, USA.
FAU - Graham, Devon L
AU  - Graham DL
FAU - Schaefer, Tori L
AU  - Schaefer TL
FAU - Grace, Curtis E
AU  - Grace CE
FAU - Braun, Amanda A
AU  - Braun AA
FAU - Burns, Lindsey N
AU  - Burns LN
FAU - Amos-Kroohs, Robyn M
AU  - Amos-Kroohs RM
FAU - Williams, Michael T
AU  - Williams MT
FAU - Vorhees, Charles V
AU  - Vorhees CV
LA  - eng
GR  - R01 DA021394/DA/NIDA NIH HHS/United States
GR  - T32 ES007051/ES/NIEHS NIH HHS/United States
GR  - DA021394/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20110628
PL  - England
TA  - Int J Neuropsychopharmacol
JT  - The international journal of neuropsychopharmacology
JID - 9815893
RN  - 0 (Biogenic Monoamines)
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - 0 (Hallucinogens)
RN  - 6LR8C1B66Q (Dizocilpine Maleate)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Acoustic Stimulation
MH  - Aging/*drug effects/*physiology
MH  - Animals
MH  - Animals, Newborn
MH  - Behavior, Animal/*drug effects
MH  - Biogenic Monoamines/*metabolism
MH  - Body Weight/drug effects
MH  - Conditioning, Psychological/drug effects
MH  - Dizocilpine Maleate/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Excitatory Amino Acid Antagonists/pharmacology
MH  - Fear/drug effects
MH  - Female
MH  - Hallucinogens/*pharmacology
MH  - Inhibition, Psychological
MH  - Male
MH  - Maze Learning/drug effects
MH  - Mortality
MH  - Motor Activity/drug effects
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reaction Time/drug effects
MH  - Reflex, Startle/drug effects
MH  - Swimming/psychology
PMC - PMC4599583
MID - NIHMS724406
EDAT- 2011/07/08 06:00
MHDA- 2012/10/20 06:00
PMCR- 2015/10/09
CRDT- 2011/07/08 06:00
PHST- 2011/07/08 06:00 [entrez]
PHST- 2011/07/08 06:00 [pubmed]
PHST- 2012/10/20 06:00 [medline]
PHST- 2015/10/09 00:00 [pmc-release]
AID - S1461145711000952 [pii]
AID - 10.1017/S1461145711000952 [doi]
PST - ppublish
SO  - Int J Neuropsychopharmacol. 2012 Jul;15(6):811-24. doi: 
      10.1017/S1461145711000952. Epub 2011 Jun 28.